By Virginia Li, Staff Writer
Amgen Inc.'s AMG 282 could allow Genentech Inc. to treat an asthma patient population not currently covered by its existing pipeline — or by any other targeted therapies in the clinic. The mAb has a novel mechanism that could serve patients with low levels of Th2 cell cytokine expression.
The deal, which Genentech disclosed on Jan. 28, gives the Roche unit exclusive, worldwide rights to the antibody against IL-1 receptor-like 1 (IL1RL1; ST2). Amgen will receive an undisclosed upfront payment and is eligible for milestones and royalties.